Dishman Carbogen Amcis Limited has informed the Exchange about Transcript
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dishman Carbogen Amcis reported strong Q4 FY26 results with revenue of INR 851 crores (up 19% YoY) and full year revenue of INR 2,932 crores (up 8%). EBITDA margin improved 200 bps to 19.3% for FY26. The company highlighted growth in high-margin ADC (linker-payload) business contributing about 25% of CDMO revenue, with expected growth to CHF 30-40 million in FY27-28. Vitamin D analogs segment showed remarkable performance with 940 bps margin improvement. The company plans to refinance INR 800 crores of high-cost India debt (currently at 10.5-11%) with cheaper Swiss franc borrowing, expected to reduce quarterly interest cost to INR 30-35 crores from Q2/Q3 FY27. India business is targeting INR 500 crore+ revenue in FY28 with a major Swiss molecule tech transfer (CHF 20-25 million annually). France subsidiary reported EUR 8 million revenue with EUR 9 million loss, expected to break even by FY28.
The strong margin improvement and debt refinancing plans are positive for shareholders, as the company targets 25% EBITDA margin by FY28. The growing ADC business and tech transfers to India should drive future profitability, while lower interest costs will boost bottom-line growth.